Bio-Techne (NASDAQ:TECH) target price raised to $115.00, reported today by Citigroup
- Updated: February 11, 2017
Bio-Techne (NASDAQ:TECH) had its target price raised to $115.00 by Citigroup in a report released 2/9/2017. The new target price indicates a possible upside of 0.15% based on the company's last stock close price.
Previously on Wednesday January 18, 2017, Deutsche Bank reported about Bio-Techne (NASDAQ:TECH) raised the target price from $0.00 to $115.00. At the time, this indicated a possible upside of 0.16%.
Yesterday Bio-Techne (NASDAQ:TECH) traded -0.29% lower at $99.86. The company’s 50-day moving average is $101.44 and its 200-day moving average is $105.62. The last stock close price is down -2.25% from the 200-day moving average, compared to the S&P 500 which has increased 0.06% over the same time. 338,999 shares of the stock were exchanged, up from an average trading volume of 177,506
See Chart Below
Bio-Techne has a 52 week low of $84.00 and a 52 week high of $117.42 with a P/E ratio of 49.21 The company’s market cap is currently $0.
About Bio-Techne (NASDAQ:TECH)
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.